Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant IFN-alpha in lymphomas.

H W Ziegler-Heitbrock1, E Thiel

  • 1Institute for Immunology, University of Munich, F.R.G.

The Journal of Investigative Dermatology
|December 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo.

Leukemia & lymphoma·2016
Same author

Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses.

Leukemia & lymphoma·2016
Same author

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Leukemia·2016
Same author

Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.

Blood cancer journal·2012
Same author

Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations.

Blood cancer journal·2012
Same author

Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same journal

Reducing plastic waste in skin-model research: Sustainable packaging as a practical first step.

The Journal of investigative dermatology·2026
Same journal

Modern serum proteomics in precision medicine: Toward disease stratification and predictive, proactive treatment strategies.

The Journal of investigative dermatology·2026
Same journal

An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.

The Journal of investigative dermatology·2026
Same journal

Residual CSB activity explains mild UV-sensitive syndrome phenotype caused by CSB mutations.

The Journal of investigative dermatology·2026
Same journal

Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.

The Journal of investigative dermatology·2026
Same journal

Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris.

The Journal of investigative dermatology·2026
See all related articles

Interferon (IFN) therapy shows palliative effects for certain lymphomas, particularly hairy-cell leukemia and low-grade non-Hodgkin lymphomas. Early-stage disease responds best, with potential for remission maintenance, though IFN is not curative.

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Malignant lymphoma encompasses various lymphoid neoplasms.
  • Interferon (IFN) therapy has been explored as a treatment modality.
  • Previous studies have investigated IFN's efficacy in different lymphoma subtypes.

Purpose of the Study:

  • To review the effectiveness of interferon (IFN) therapy in malignant lymphoma.
  • To analyze the palliative and potential curative roles of IFN.
  • To discuss IFN's application in early-phase treatment and remission maintenance.

Main Methods:

  • Systematic review of existing studies on IFN therapy for malignant lymphoma.
  • Analysis of treatment regimens, dose levels, and patient responses.
  • Evaluation of IFN efficacy based on disease stage and subtype.

Related Experiment Videos

Main Results:

  • IFN therapy has not demonstrated curative potential in malignant lymphoma.
  • A substantial palliative effect was observed in hairy-cell leukemia and some low-grade non-Hodgkin lymphomas.
  • Early-stage lymphomas, including chronic lymphocytic leukemia, showed better responsiveness compared to progressed disease post-chemotherapy.

Conclusions:

  • Interferon therapy offers palliative benefits for specific lymphoma types, especially in early stages.
  • IFN may play a role in remission maintenance strategies.
  • Curative potential of IFN therapy in malignant lymphoma remains limited.